Vor BiopharmaVOR -3.09%32 14-Day RSI is 63.44 as of Jul. 11, 2026. GuruFocus rates VOR with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,420 Biotechnology companies, Vor Biopharma ranks worse than 90.63% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-11), Vor Biopharma's 14-Day RSI is 63.44.
The industry rank for Vor Biopharma's 14-Day RSI or its related term are showing as below:
VOR's 14-Day RSI is ranked worse than 90.63% of 1420
companies
in the Biotechnology industry
Industry Median: 48.885
vs VOR: 63.44
Vor Biopharma (NAS:VOR) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Vor Biopharma 14-Day RSI Related Terms
VOR vs ODTX, ANNX, ABUS: 14-Day RSI Comparison
For the Biotechnology subindustry, Vor Biopharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vor Biopharma 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vor Biopharma's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Vor Biopharma's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vor Biopharma (VOR) has a 14-Day RSI of 63.44 as of Jul. 11, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Vor Biopharma and its competitors. According to the industry distribution chart, Vor Biopharma ranks #1287 out of 1420 companies in the Biotechnology industry, placing it in the top 90.6%.
Is Vor Biopharma's 14-Day RSI too high?
Vor Biopharma's current 14-Day RSI is 63.44. The Biotechnology industry median 14-Day RSI is 48.89. Vor Biopharma's value of 63.44 is 29.8% above this industry median. Based on the distribution chart, Vor Biopharma ranks #1287 out of 1420 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vor Biopharma has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Vor Biopharma's 14-Day RSI compare to ODTX and ANNX?
According to the Biotechnology industry distribution chart, Vor Biopharma ranks #1287 out of 1420 companies for 14-Day RSI. This places Vor Biopharma in the lower half of its industry. The industry median 14-Day RSI is 48.89. Vor Biopharma's value of 63.44 is 29.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.89, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vor Biopharma's current 14-Day RSI of 63.44 is 29.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Vor Biopharma and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vor Biopharma's current 14-Day RSI is 63.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vor Biopharma stock overvalued right now?
Vor Biopharma (VOR) has a current 14-Day RSI of 63.44. The current 14-Day RSI is 63.44 and 29.8% above the Biotechnology industry median of 48.89. Vor Biopharma's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Vor Biopharma (VOR), the current 14-Day RSI is 63.44 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
32GF Score
Get the complete analysis for VOR
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VOR has been successfully added to your 